RxDoctor Payments Data

Mary Santiago, MD

Family Medicine · Fulshear, TXNPI 1528097268

Payments from drug & device makers

$9,447in general payments, 2019–2025

Across 486 payments — averaging $19.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$1K
  • AstraZeneca$1K
  • Lilly USA, LLC$785
  • Pfizer$673
  • Idorsia Pharmaceuticals US Inc$319
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$9,39799%
  • Education$491%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,447 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$119,017
Medicare patients
461
Services billed
2,146

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide74$111,682
EliquisApixaban27$33,352
MounjaroTirzepatide22$31,300
FarxigaDapagliflozin Propanediol30$20,497
Nurtec OdtRimegepant Sulfate12$19,299
XareltoRivaroxaban14$10,597
MyrbetriqMirabegron13$9,184
JardianceEmpagliflozin11$8,120
QuviviqDaridorexant Hcl17$8,070
SymbicortBudesonide/Formoterol Fumarate11$2,477
Atorvastatin Calcium203$2,270
Albuterol Sulfate HfaAlbuterol Sulfate83$1,687
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,637
SynthroidLevothyroxine Sodium25$1,604
Gabapentin70$1,536

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,846$111,68274 claims
PfizerEliquis, Nurtec Odt, Paxlovid$673$54,08151 claims
Lilly USA, LLCMounjaro$785$31,30022 claims
AstraZenecaFarxiga, Symbicort$1,228$22,97441 claims
Johnson & JohnsonXarelto$103$10,59714 claims
Astellas Pharma US IncMyrbetriq$15$9,18413 claims
Boehringer IngelheimJardiance$100$8,12011 claims
Idorsia Pharmaceuticals US IncQuviviq$319$8,07017 claims
AbbVieSynthroid$1,482$1,60425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Fulshear

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →